Comparative Pharmacology
Head-to-head clinical analysis: BUTOCONAZOLE NITRATE versus EXTINA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BUTOCONAZOLE NITRATE versus EXTINA.
BUTOCONAZOLE NITRATE vs EXTINA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inhibits fungal cytochrome P450 14α-demethylase, blocking ergosterol synthesis and disrupting fungal cell membrane integrity.
Antifungal agent that inhibits the enzyme 14α-demethylase, blocking the conversion of lanosterol to ergosterol, an essential component of fungal cell membranes.
Intravaginal administration: 100 mg (one applicatorful of 2% cream) once daily for 3 days; or 100 mg (one suppository) once daily for 3 days; or 5 g (one applicatorful of 4% cream) as a single dose.
2.5% to 3.5% solution applied topically twice daily for 4 weeks.
None Documented
None Documented
Terminal half-life is approximately 21–24 hours, supporting once-daily or twice-weekly dosing for vaginal candidiasis.
Terminal elimination half-life is approximately 24-32 hours in adults, allowing once-daily dosing. Half-life may be prolonged in patients with renal impairment.
Primarily hepatic metabolism with <5% excreted unchanged in urine; fecal elimination accounts for ~30% of metabolites.
Primarily renal excretion of unchanged drug (approximately 80-90% of the absorbed dose), with minor hepatic metabolism and fecal elimination (<10%).
Category A/B
Category C
Antifungal
Antifungal